Overview

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Trans

Status:
Withdrawn

Trial end date:
2025-01-28

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for Hematopoietic Stem Cell Transplantation (HSCT).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborators:

argenx
argenx BVBA

Treatments:

Azacitidine